Glaukos Enters Exclusive License Agreement With RevOpsis Therapeutics To Develop And Commercialize RO-104, A Novel Tri-Specific Biologic
Development targeted for the treatment of neovascular age-related macular degeneration (nAMD), diabetic macula edema (DME), diabetic retinopathy (DR), and retinal vein occlusion (RVO). The agreement also grants Glaukos
Glaukos bought the rights to develop a new eye medicine. Watch if they can turn this into a real product that helps patients.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.